Along with plant-based foods and beauty, the use of plants in skin care is only growing in popularity. That, according to the Plants used to treat skin diseases report in the U.S. National Library of Medicine is happening because of "several advantages such as often having fewer side-effects, better patient tolerance, being relatively less expensive and acceptable due to a long history of use." In fact, over the last 17 years, 31 plants have been found to be effective in treating various skin issues.
For example, according to the report noted above, Achyranthes aspera is used in boils, scabies and eruptions of skin and other skin diseases. Aloe vera has shown very good results in skin diseases. Brassica oleraceae has helped with significant reduction of tumors, which was observed in mice. Calendula officinalis has been used as remedies for burns, bruises and cutaneous and internal inflammatory diseases of several origins. Echinacea has been applied to and used to treat skin problems such as skin boils, wounds, ulcers, burns, and psoriasis. However, that's just a fraction of plant-based treatments. Such news is creating substantial opportunity for companies that have a focus on antivirals, including Better Plant Sciences Inc. (CSE:PLNT)(OTC:BOSQF), Merck & Co. Inc. (NYSE:MRK), GlaxoSmithKline PLC (NYSE:GSK), Johnson & Johnson (NYSE:JNJ), and Roche Holdings (OTC:RHHBY).
Better Plant Sciences Inc. (CSE:PLNT)(OTC:BOSQF) BREAKING NEWS: Better Plant Sciences Inc. announces that it has conducted research and development into plant-based topical products that fight against or prevent infectious diseases leading to the submission of a Natural Health Product ("NHPN") application for a plant-based, antiseptic skin ointment to Health Canada to obtain an NPN number for the product.
"This plant-based skin ointment was developed using the principles of Ayurveda. We have spent the last six months working to identify the plants with the most active compounds with antibacterial and antiviral properties," says Bhavna Solecki, Director of Research and Product Development at Better Plant Sciences. "We are very pleased with the resulting plant-based antiseptic skin repair and healing ointment formula we have developed to be used to help heal minor skin wounds, cuts, burns, and bruises."
According to the Natural Health Products Regulations, compendial product licence applications are processed within 60-days of receipt. GM Insights reported that the global wound care biologics market was worth US$ 1.40 Billion in 2018 and is expected to reach a value of US$ 2.5 billion by 2025 with a CAGR of around 9%. Wound care biologics refer to drugs extracted or semi-synthesized from natural sources which are used for controlling and healing infections.
The Better Plant Sciences research and development team focused on using polyherbal combinations, which use a group of plants to achieve an effective therapeutic effect. In Ayurveda, most classical preparations are polyherbal, involving a combination of 3 to 30 plants that are combined in precise ratios to achieve the desired result.
"During the compounding process, one or two of the plants will be active and the others play a supporting role. The supporting herbs have different therapeutic values calculated for different purposes, which act as catalysts to help proper absorption, transportation, and to reduce toxicity," added Solecki. "We use spices because the phytochemicals within spices are secondary metabolites, which serve to protect against damage by insects, animals, fungi, pathogens, and parasites."
Other related developments from around the markets include:
Merck & Co. Inc. (NYSE:MRK) announced that the pivotal Phase 3 KEYNOTE-590 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, in combination with chemotherapy (cisplatin plus 5-fluorouracil [5-FU]), met its primary endpoints of overall survival (OS) and progression-free survival (PFS) for the first-line treatment of patients with locally advanced or metastatic esophageal cancer. Based on an interim analysis conducted by an independent Data Monitoring Committee, KEYTRUDA in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in OS and PFS compared with chemotherapy (cisplatin plus 5-FU), the current standard of care, in the intention-to-treat (ITT) population. The study also met the key secondary endpoint of objective response rate (ORR), with significant improvements for KEYTRUDA in combination with chemotherapy compared with chemotherapy alone. The safety profile of KEYTRUDA in this trial was consistent with that observed in previously reported studies. Results will be shared with global regulatory authorities and have been submitted for presentation at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. "Esophageal cancer is a devastating malignancy with a high mortality rate and few treatment options in the first-line setting beyond chemotherapy," said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. "In this pivotal study, KEYTRUDA plus chemotherapy resulted in superior overall survival compared with the current standard of care in the full study population and across all patient groups evaluated. These results build upon our research reinforcing the survival benefits of KEYTRUDA, and we look forward to engaging regulatory authorities as quickly as possible."
GlaxoSmithKline PLC (NYSE:GSK) announced that patient dosing has begun in a phase III clinical programme investigating its 5-in-1 meningitis (MenABCWY) vaccine candidate compared to licensed meningococcal vaccines, Bexsero and Menveo. Emmanuel Hanon, Senior Vice President and Head of Vaccines R&D for GSK, said: "Entering the final stage of clinical trials with our 5-in-1, MenABCWY vaccine candidate is a major step toward GSK's goal of reducing meningococcal disease around the world. This vaccine candidate builds on the heritage of Bexsero and Menveo and we would like to thank all the scientific researchers, medical partners, advocates and families around the world who also hope for a successful outcome."
Johnson & Johnson (NYSE:JNJ) announced Lewis Cantley, Ph.D., of Weill Cornell Medicine and NewYork-Presbyterian as the winner of the 2020 Dr. Paul Janssen Award for Biomedical Research for his incisive research revealing the fundamental aspects of metabolism that have profound implications for the understanding, diagnosis and treatment of human diseases such as cancer and diabetes. "Like all of the past Dr. Paul Janssen Award winners, and indeed like Dr. Janssen himself, Dr. Cantley challenged the status quo, asked provocative questions, and tirelessly followed his curiosity to uncover scientific insights that have led to an expanded understanding of human biology and the development of solutions that can improve people's lives," said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson. "We are proud to honor the legacy of Dr. Janssen by celebrating today's research pioneers like Dr. Cantley."
Roche Holdings (OTC:RHHBY) and Regeneron announced that they are joining forces in the fight against COVID-19 to develop, manufacture and distribute REGN-COV2, Regeneron's investigational antiviral antibody combination, to people around the globe. REGN-COV2 could provide a much-needed treatment option for people already experiencing symptoms of COVID-19, and also has the potential to prevent infection in people exposed to the virus, thus slowing the spread of the global pandemic. This collaboration is expected to increase supply of REGN-COV2 to at least three and a half times the current capacity, with the potential for even further expansion. REGN-COV2 is currently being studied in two Phase 2/3 clinical trials for the treatment of COVID-19 and in a Phase 3 trial for the prevention of COVID-19 in household contacts of infected individuals. If it proves safe and effective in clinical trials and regulatory approvals are granted, Regeneron will distribute and record sales for REGN-COV2 in the U.S. and Roche will be responsible for distribution outside the U.S.
Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Better Plant Sciences Inc.
has paid three thousand five hundred dollars for advertising and marketing services to be distributed by Winning Media. Winning Media is only compensated for its services in the form of cash-based compensation. Winning Media owns ZERO shares of Better Plant Sciences Inc.
Please click here for full disclaimer.
Contact Information:
2818047972
[email protected]
